Pricing Log in Create free account
Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

KRYS Healthcare Biotechnology

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue
+30.2%
EPS
−22.3%
Free cash flow
+137.8%

Quarter to September 2026, against a year earlier

300.31 0.06 +0.02%
Market cap
$8.9B
P/E
39.2×
Fwd P/E
45.7×
Dividend yield
—
F-score
7/9
Altman Z
39.03
Beneish M
−2.27
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Krystal Biotech, Inc. 10-Q filed Aug 3, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 7:03 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 4, 2026: 24 added · 4 removed · 33 modified; 13 with only figures updated

  1. Modified · SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

    •our commercialization plans in the United States, the European Union (the “EU”), Japan, the United Kingdom (the “UK”), and elsewhere for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt) for the treatment of dystrophic epidermolysis bullosa (“DEB”), including timing of pricing negotiations and potential commercial launches in Europe;